Management of cancer in the older person: A practical approach

Oncologist

Volumn 5, Issue 3, 2000, Pages 224-237

  Balducci, Lodovico ^a   Extermann, Martine ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Cancer; Elderly; Geriatric assessment; Older person; Pharmacokinetics

Indexed keywords

AMIFOSTINE; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DICHLOROMETHOTREXATE; EPIPODOPHYLLOTOXIN; ERYTHROPOIETIN; FLUDARABINE; FLUOROURACIL; HEMOGLOBIN; HYDROXYUREA; IFOSFAMIDE; INTERLEUKIN 11; MELPHALAN; METHOTREXATE; TAXANE DERIVATIVE;

AGING; ALGORITHM; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; DRUG DISTRIBUTION; DRUG MEGADOSE; DRUG URINE LEVEL; GERIATRICS; HUMAN; KIDNEY FUNCTION; LIFE EXPECTANCY; LIVER METABOLISM; PRIORITY JOURNAL; RISK ASSESSMENT; SCREENING TEST;

EID: 0033920730     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.5-3-224     Document Type: Article

References (104)

1. Yancik R, Ries LA. Aging and cancer in America: demographic and epidemiologic perspectives. Hematol Oncol Clin North Am 2000;14:17-24.
2. Yancik RM, Ries L. Cancer and age: magnitude of the problem. In: Balducci L, Lyman GH, Ershler WB, eds. Comprehensive Geriatric Oncology. London: Harwood Academic Publishers, 1997:95-103.
3. Balducci L, Extermann M. Cancer and aging. An evolving panorama. Hematol Oncol Clin North Am 2000;14:1-16.
4. Duthie E. Physiology of aging: relevance to symptom perceptions and treatment tolerance. In: Balducci L, Lyman GH, Ershler WB, eds. Comprehensive Geriatric Oncology. London: Harwood Academic Publishers, 1998:247-262.
5. Balducci L, Corcoran MB. Antineoplastic chemotherapy of the older cancer patient. Hematol Oncol Clin North Am 2000;14:193-212.
6. Ania BJ, Suman VJ, Fairbanks VF et al. Incidence of anemia in older people: an epidemiologic study of a well defined population. J Am Geriatr Soc 1997;45:823-831.
7. Ania BJ, Suman VJ, Fairbanks VF et al. Prevalence of anemia in medical practice: community versus referral patients. Mayo Clin Proc 1994;69:730-735.
8. Izaks GJ, Westendorp RG, Knook DL. The definition of anemia in the older person. JAMA 1999;281:1714-1717.
9. Moscinsky LC. Hemopoiesis and aging. In: Balducci L, Lyman GH, Ershler WB, eds. Comprehensive Geriatric Oncology. London: Harwood Academic Publisher, 1998:399-412.
10. Pierelli L, Perillo A, Greggi S et al. Erythropoietin addition to granulocyte-colony stimulating factor abrogates life-threatening neutropenia and increases peripheral blood progenitor-cell mobilization after epirubicin, paclitaxel and cisplatin in combination chemotherapy. J Clin Oncol 1999;17:1288-1296.
11. Ratain MJ, Schilsky RL, Choi KE et al. Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability. Clin Pharmacol Ther 1989;45:226-233.
12. Silber JH, Fridman M, Di Paola RS et al. First-cycle blood counts and subsequent neutropenia, dose reduction or delay in early stage breast cancer therapy. J Clin Oncol 1998;16:2392-2400.
13. Extermann M, Chen A, Cantor AB et al. Predictors of toxicity from chemotherapy in older patients. Proc Am Soc Clin Oncol 2000;19:617a.
14. Balducci L, Extermann M. Cancer chemotherapy in the older patient: what the medical oncologist needs to know. Cancer 1997;80:1317-1322.
15. Cova D, Beretta G, Balducci L. Cancer chemotherapy in the older patients. In: Balducci L, Lyman GH, Ershler WB, eds. Comprehensive Geriatric Oncology. London, England: Harwood Academic Publishers, 1998:429-442.
16. Dorshow JH. Anthracyclines and anthracendiones. In: Chabner BA, Longo DL, eds. Cancer Chemotherapy and Biotherapy. Philadelphia: Lippincott-Raven, 1996:409-434.
17. Gelman RS, Taylor SG. Cyclophosphamide, methotrexate and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol 1984;2:1406-1414.
18. Borkowski JM, Duerr M, Donehower RC et al. Relation between age and clearance rate of nine investigational anti-cancer drugs from phase I pharmacokinetics data. Cancer Chemother Pharmacol 1994;33:493-496.
19. Branch RA, Herbert CM, Read AE. Determinants of serum antipyrine half-lives in patients with liver disease. Gut 1973;14:569-573.
20. Durnas C, Loi CM, Cusack BJ. Hepatic drug metabolism and aging. Clin Pharmacokinet 1990;19:359-389.
21. Montamat SC, Cusack BJ, Vestal RE. Management of drug therapy in the elderly. N Engl J Med 1989;321:303-309.
22. Vestal RE. Aging and pharmacology. Cancer 1997;80:1302-1310.
23. Corcoran MB. Polypharmacy in the older patient. In: Balducci L, Lyman GH, Ershler WB, eds. Comprehensive Geriatric Oncology. London: Harwood Academic Publishers, 1997:525-532.
24. Sheehan DC, Forman WB. Symptomatic management of the older person with cancer. Clin Geriatr Med 1997;13:203-219.
25. Mulder GJ. Glucuronidation and its role in regulation of biological activities of drugs. Ann Rev Pharmacol Toxicol 1992;32:25-49.
26. Abbott FV, Palmour RM. Morphine 6-glucuronide: analgesic effects and receptor binding profile in rats. Life Sci 1988;43:1685-1691.
27. Rudd GN, Hartley JA, Souhami RL. Persistence of cisplatin-induced DNA interstrand crosslinking in peripheral blood mononuclear cells from elderly and younger individuals. Cancer Chemother Pharmacol 1995;35:323-326.
28. Stein BN, Petrelli NJ, Douglass HO et al. Age and sex are independent predictors of 5-fluorouracil toxicity. Cancer 1995;75:11-17.
29. Lancet JE, Willman CL, Bennett JM. Acute myelogenous leukemia and aging: clinical interactions. Hematol Oncol Clin North Am 2000;16:251-267.
30. Campisi J. Cancer and age: the double sword of replicative senescence. J Am Geriatr Soc 1997;45:482-488.
31. Rockwell S, Hughes CS, Kennedy KA. Effects of host age on microenvironmental heterogeneity and efficacy of combined modality treatment in solid tumors. Int J Radiat Oncol Biol Phys 1991;20:259-263.
32. Balducci L, Hardy CL, Lyman GH. Hemopoietic reserve in older cancer patients: clinical and economical considerations. Cancer Control JHLMCC 2000 (in press).
33. Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin induced congestive heart failure. Ann Intern Med 1979;91:710-717.
34. Longo DL, Young RC, Wesley M et al. Twenty years of MOPP therapy for Hodgkin's Disease. J Clin Oncol 1986;4:1295-1306.
35. Gottlieb D, Bradstock K, Koutts J et al. The neurotoxicity of high-dose cytosine arabinoside is age-related. Cancer 1987;60:1439-1441.
36. Christman K, Muss HB, Case D et al. Chemotherapy of metastatic breast cancer in the elderly. JAMA 1992;268:57-62.
37. Ibrahim N, Frye DK, Buzdar AU et al. Doxorubicin based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome. Arch Intern Med 1996;156:882-888.
38. Begg CB, Carbone P. Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group. Cancer 1983;52:1986-1992.
39. Giovanazzi-Bannon S, Rademaker A, Lai G et al. Treatment tolerance of elderly cancer patients entered onto phase II clinical trials. An Illinois cancer center study. J Clin Oncol 1994;12:2447-2452.
40. Zinzani PL, Storti S, Zaccaria A et al. Elderly aggressive histology non-Hodgkin's lymphoma: first line VNCOP-B regimen experience on 350 patients. Blood 1999;94:33-38.
41. Sonneveld P, de Ridder M, van der Lelie H et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP vs CNOP chemotherapy. J Clin Oncol 1995;13:2530-2539.
42. Gomez H, Mas L, Casanova L et al. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity. J Clin Oncol 1998;16:2352-2358.
43. Tirelli U, Errante D, Van Glabbeke M et al. CHOP is the standard regimen in patients ≥70 years of age with intermediate and high grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol 1998;16:27-34.
44. Bastion Y, Blay J-Y, Divine M et al. Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment and survival. A Groupe d'Etude des Lymphomes de l'Adulte Study on 453 patients older than 69 years. J Clin Oncol 1997;15:2945-2953.
45. Bertini M, Freilone R, Vitolo U et al. The treatment of elderly patients with aggressive non-Hodgkin's lymphomas: feasiblity and efficacy of an intensive multidrug regimen. Leuk Lymphoma 1996;22:483-493.
46. O'Reilly SE, Connors JM, Howdle S et al. In search of an optimal regimen for elderly patients with advanced-stage diffuse large-cell lymphoma: results of a Phase II study of P/DOCE chemotherapy. J Clin Oncol 1993;11:2250-2257.
47. Armitage JO, Potter JF. Aggressive chemotherapy for diffuse histiocytic lymphoma in the elderly. J Am Geriatr Soc 1984;32:269-273.
48. Rowe JM, Andersen J, Mazza JJ et al. A randomized-placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group. Blood 1995;86:457-462.
49. Schiffer CA. Hematopoietic growth factors as adjuncts to the treatment of acute myeloid leukemia. Blood 1996;88:3675-3685.
50. Cleeland CS, Demetri GD, Glaspy J et al. Identifying hemoglobin levels for optimal quality of life. Results of an incremental analysis. Proc Am Soc Clin Oncol 1999;16:2215a.
51. Gabrilove JL, Einhorn LH, Livingston RB et al. Once weekly dosing of epoietin alfa is similar to three-times weekly dosing in increasing hemoglobin and quality of life. Proc Am Soc Clin Oncol 1999;18:574a.
52. Marcantonio ER, Goldman L, Orav EJ et al. The association of intraoperative factors with the development of postoperative delirium. Am J Med 1998;105:380-384.
53. Legha SS, Benjamin RS, MacKay B et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982;96:133-139.
54. Wiseman LR, Spencer CM. Dexrazoxane: a review of its use as a cardioprotective agent in patients receiving anthracycline-based chemotherapy. Drugs 1998;56:385-403.
55. Schagen SB, Van Dam FS, Muller MJ et al. Cognitive deficit after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 1999;85:640-650.
56. Rubin EH, Andersen JW, Berg DT et al. Risk factors for high dose cytarabine neurotoxicity: an analysis of a cancer and acute leukemia group B trials in patients with acute myeloid leukemia. J Clin Oncol 1992;10:948-953.
57. Balducci L, Yates GK. Guidelines for the management of the older person with cancer. Oncology 2000 (in press).
58. Balducci L, Schonwetter R, Gray J et al. Individualized treatment of the older cancer patient: a decision analysis. J Am Geriatr Soc 1990;58:61a.
59. Balducci L, Stanta G. Cancer in the frail patient: a coming epidemic. Hematol Oncol Clin North Am 2000;14:235-250.
60. Hogan DB, Ebly EM, Fung TS. Disease, disability, and age in cognitively intact seniors: results from the Canadian study of health and aging. J Gerontol 1999;54A:M77-M82.
61. Cassel CK. Money, medicine and Methuselah. Mt. Sinai J Med 1998;65:237-245.
62. Rockwood K, Stadnyk K, MacKnight C et al. A brief chemical instrument to classify frailty in elderly people. Lancet 1999;353:205-206.
63. Hamermann D. Toward an understanding of frailty. Ann Intern Med 1999;130:945-950.
64. Anderson S, Brenner BM. Effects of aging on the renal glomerulus. Am J Med 1986;80:435-442.
65. Ershler WB. Interleukin-6: a cytokine for gerontologists. J Am Geriatr Soc 1993;41:176-181.
66. Hack V, Breitkreutz R, Kinscherf R et al. The redox state as a correlate of senescence and wasting and as a target for therapeutic intervention. Blood 1998;92:59-67.
67. Extermann M, Aapro M. Assessment of the older cancer patient. Hematol Oncol Clin North Am 2000;14:63-77.
68. Markson EW. Functional, social and psychological disability as causes of loss of weight and independence in older community-living people. Clin Geriatr Med 1997;13:639-652.
69. Hebert R. Functional decline in old age. CMAJ 1997;157:1037-1045.
70. Wagner EH. Preventing decline in function. Evidence from randomized trials around the world. West J Med 1997;167:295-298.
71. Extermann M. Assessment of comorbidity. CRC Crit Review Hematol Oncol 2000;14:63-78.
72. Fried LP, Storer DJ, King DE et al. Diagnosis of illness presentation in the elderly. J Am Geriatr Soc 1991;39:117-123.
73. Satariano WA, Ragland DR. The effect of comorbidity on 3-year survival of women with primary breast cancer. Ann Intern Med 1994;120:104-110.
74. Coebergh JW, Janssen-Heijnen ML, Razenberg PP. Prevalence of co-morbidity in newly diagnosed patients with cancer: a population-based study. Crit Rev Oncol Hematol 1998;27:97-100.
75. Verdery RB. Failure to thrive in old age: follow-up on a workshop. J Gerontol A Biol Sci Med Sci 1997;52:M333-M336.
76. Tinetti ME, McAvay G, Claus EB et al. A multifactorial intervention to reduce the risk of falling among elderly people living in the community. N Engl J Med 1994;331:821-827.
77. Inouye SK, Bogardus ST, Charpentier PA et al. A multi-component intervention to prevent delirium in hospitalized older patients. N Engl J Med 1999;340:669-676.
78. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State." A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
79. Reuben DB, Franck JC, Hirsch SH et al. A randomized clinical trial of outpatient comprehensive geriatric assessment (CGA), coupled with an intervention, to increase adherence to recommendations. J Am Geriatr Soc 1999;47:269-276.
80. Inoyue SK, Peduzzi PN, Robison JT et al. Importance of functional measures in predicting mortality among older hospitalized patients. JAMA 1998;279:1187-1193.
81. Alessi CA, Stuck AE, Aronow HU et al. The process of care in preventive in-home comprehensive geriatric assessment. J Am Geriatr Soc 1997;45:1044-1050.
82. Gillespie LD, Gillespie WJ, Cumming R et al. Interventions to reduce the incidence of falling in the elderly. The Cochrane Data base of Systematic Review. Vol 3, 1998 (http//www.cochrane.co.uk).
83. Reuben DB, Rubenstein LV, Hirsch SH et al. Value of functional status as predictor of mortality. Am J Med 1992;93:663-669.
84. Siu AL, Moshita L, Blaustein J. Comprehensive geriatric assessment in a day hospital. J Am Geriatr Soc 1994;42:1094-1099.
85. Barberger-Gateau P, Fabrigoule C, Helmer C et al. Functional impairment in instrumental activities of daily living: an early clinical sign of dementia? J Am Geriatr Soc 1999;47:456-462.
86. Monfardini S, Ferrucci L, Fratino L et al. Validation of a multidimensional evaluation scale for use in elderly cancer patients. Cancer 1996;77:395-401.
87. Extermann M, Overcash J, Lyman GH et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 1998;16:1582-1587.
88. Piccirillo JF, Feinstein AR. Clinical symptoms and comorbidity: significance for the prognostic classification of cancer. Cancer 1996;77:834-842.
89. Charlson M, Szatrowski TP, Peterson M et al. Validation of a combined comorbidity index. J Clin Epidemiol 1994;47:1245-1251.
90. Conwell Y, Forbes NT, Cox C et al. Validation of a measure of physical illness burden at autopsy: the cumulative illness rating scale. J Am Geriatr Soc 1993;41:38-41.
91. Eagles JM, Beattie JAG, Restall DB et al. Relation between cognitive impairment and early death in the elderly. Br Med J 1990;300:239-240.
92. Bruce ML, Hoff RA, Jacobs SC et al. The effect of cognitive impairment on 9-year mortality in a community sample. J Gerontol B Psychol Sci Soc Sci 1995;50;289-296.
93. Lyness JM, Noel TK, Cox C et al. Screening for depression in elderly primary care patients: a comparison of the center for Epidemiologic Studies Depression Scale and the Geriatric Depression Scale. Arch Intern Med 1997;157:449-454.
94. Covinsky KE, Kahana E, Chin MH et al. Depressive symptoms and three year mortality in older hospitalized medical patients. Ann Intern Med 1999;130:563-569.
95. Bruce ML, Leaf PJ, Rozal GP et al. Psychiatric status and nine year mortality data in the New Haven Epidemiologic Catchment Area Study. Am J Psych 1994;151:716-721.
96. Guigoz Y, Vellas B, Garry PJ. Mininutritional assessment: a practical assessment tool for grading the nutritional state of elderly patients. In: Facts, Research, Interventions in Geriatrics. New York: Serdi Publishing Company, 1997:15-60.
97. Balducci L, Wallace C, Khansur T et al. Nutrition, cancer, and aging: an annotated review. J Am Geriatr Soc 1986;34:127-136.
98. Aslani A, Smith RC, Allen BJ. The predictive value of body protein for chemotherapy induced toxicity. Cancer 2000;88:796-803.
99. Tckemedyian S, Heber D. Nutritional therapy. In: Balducci L, Lyman GH, Ershler W, eds. Comprehensive Geriatric Oncology. London: Harwood Academic Publishers, 1998:765-779.
100. Weitzner MA, Haley WE, Chen H. The family caregiver of the older cancer patient. Hematol Oncol Clin North Am 2000;14:269-281.
101. Balducci L, Extermann M. Management of the frail cancer patient. Crit Rev Hematol Oncol 2000;33:143-148.
102. Lachs MS, Feinstein AR, Coonley LM et al. A simple procedure for general screening for functional disability in elderly patients. Ann Intern Med 1990;112:699-706.
103. Hutchins LF, Unger JM, Crowley JJ et al. Underepresentation of patients 65 years of age and older in cancer treatment trials. N Engl J Med 1999;341:2061-2067.
104. Guadagnoli E, Shapiro C, Gurwitz JH et al. Age-related patterns of care: evidence against ageism in the treatment of early-stage breast cancer. J Clin Oncol 1997;15:2338-2344.